Ramucirumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1552 publications

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Journal: Journal of comparative effectiveness research

Published: August 12, 2026

Corrigendum to 'Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI' Journal of Pharmaceutical Sciences Volume 115, Issue 9, September 2026, 104402.

Corrigendum to 'Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI' Journal of Pharmaceutical Sciences Volume 115, Issue 9, September 2026, 104402.

Journal: Journal of pharmaceutical sciences

Published: August 04, 2026

Esophago-pericardial fistula and gastric perforation after esophageal stenting during ramucirumab treatment.

Esophago-pericardial fistula and gastric perforation after esophageal stenting during ramucirumab treatment.

Journal: Revista espanola de enfermedades digestivas

Published: July 13, 2026

Comment on "Theranostic Potential of Ramucirumab Functionalized Magnetoliposomes for Targeted Delivery of Sorafenib and MRI".

Comment on "Theranostic Potential of Ramucirumab Functionalized Magnetoliposomes for Targeted Delivery of Sorafenib and MRI".

Journal: Journal of pharmaceutical sciences

Published: July 06, 2026

Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report.

Pathological Complete Response in a Patient With HER2-Negative Esophagogastric Junction Cancer Undergoing Conversion-Intent Surgery After Ramucirumab Plus Paclitaxel Following Nivolumab-Based Chemotherapy: A Case Report.

Journal: Journal of gastrointestinal cancer

Published: June 23, 2026

Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel-Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan.

Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel-Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan.

Journal: Cancers

Published: June 16, 2026

A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan

A Case of Recurrent Esophagogastric Junction Cancer with Long‒Term Complete Response by Trastuzumab Deruxtecan

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: May 25, 2026

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics.

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics.

Journal: Frontiers in pharmacology

Published: May 21, 2026

Targetable genes associated with hematogenous metastasis in gastric cancer using the TCGA database.

Targetable genes associated with hematogenous metastasis in gastric cancer using the TCGA database.

Journal: Korean journal of clinical oncology

Published: May 14, 2026

The VEGFA-VEGFR2 axis Drives Malignant Potential in Oral Squamous Cell Carcinoma by Promoting Stemness and Cell Proliferation.

The VEGFA-VEGFR2 axis Drives Malignant Potential in Oral Squamous Cell Carcinoma by Promoting Stemness and Cell Proliferation.

Journal: The American journal of pathology

Published: May 08, 2026

Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.

Chemotherapy After Immune Checkpoint Inhibitor Exposure in Advanced Gastric Cancer: Clinical Evidence and Treatment Sequencing in the ICI Era.

Journal: Journal of gastrointestinal cancer

Published: May 05, 2026

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 05, 2026

Showing 1-12 of 1,552

Last Updated: 09/26/2026